Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

No longer available 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 1Expanded_access 1

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Klatskin Tumor 2Cholangiocarcinoma 2Sarcoma, Kaposi 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Lymphoma 1Liver Neoplasms 1Epstein-Barr Virus Infections 1Carcinoma, Hepatocellular 1Acquired Immunodeficiency Syndrome 1

Interventions

Gemcitabine 6Cisplatin 6Capecitabine 6Liver Transplantation 4Fluorouracil 4Specimen Handling 3Radiosurgery 3Oxaliplatin 3Magnetic Resonance Spectroscopy 3toripalimab 2dehydroftorafur 2Self Expandable Metallic Stents 2Platinum 2Leucovorin 2Biopsy 23-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide 21,2-diaminocyclohexaneplatinum II citrate 2trisacryl gelatin microspheres 1tremelimumab 1trametinib 1tislelizumab 1temoporfin 1sacituzumab govitecan 1ricolinostat 1pembrolizumab 1lenvatinib 1gemcitabine-oxaliplatin regimen 1fludarabine 1durvalumab 1binimetinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Klatskin Tumor × 3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide × Clear all
NCT03377179 2025-07-23

A Study of ABC294640 Alone and in Combination With HCQ Sulfate in the Treatment of Advanced Cholangiocarcinoma

RedHill Biopharma Limited

Phase 2 Completed
65 enrolled
Gastrointestinal

Cholangiocarcinoma, Klatskin Tumor

NCT03414489 2025-03-18

Expanded Access for the Treatment of Advanced Cholangiocarcinoma With ABC294640 (Yeliva ®)

RedHill Biopharma Limited

No longer available
Gastrointestinal

Cholangiocarcinoma, Klatskin Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡